Health Care • Biotechnology: Pharmaceutical Preparations
$927.89 ▲ +109.12
(+13.33%)
MKT CAP: $84.30B • VOL: 2.87M
52W L $592 52W H $935
REGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $14.34B | $14.20B | $13.12B |
| YoY Revenue Growth % | +1.0% | +8.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $3.58B | $3.99B | $4.05B |
| Operating Margin % | 24.9% | 28.1% | 30.9% |
| Net Income (GAAP) | $4.50B | $4.41B | $3.95B |
| EBITDA (Normalized) | $4.09B | $4.50B | $4.52B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $4.98B | $4.42B | $4.59B |
| Capital Expenditures (CapEx) | $645.4M | $639.1M | $590.3M |
| Free Cash Flow (FCF) | $4.33B | $3.78B | $4.00B |
| FCF Margin % | 30.2% | 26.6% | 30.5% |
| Return on Invested Capital (ROIC %) | 9.4% | 10.9% | 11.4% |
| Cash & Short-Term Equivalents | $3.12B | $2.49B | — |
| Total Debt (Short + Long Term) | $1.99B | $1.98B | $10.85B |
| Total Stockholders' Equity | $31.26B | $29.35B | $22.25B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR REGN.